Giovanni Geronilla
General Practice · Suffolk, VANPI 1972759439
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $995 and has fallen 98.5% since, to $15 in 2023. Among general practice clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$363
- AstraZeneca$235
- GSK$209
- Merck$203
- Boehringer Ingelheim$181
- Amgen$160
- plus $1K from 20 others
Across 6 payments — averaging $1618.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$10K
What the payments were for
- Food & beverage$2,27596%
- Education$954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $363 |
| AstraZeneca | 15 | $235 |
| GSK | 11 | $209 |
| Merck | 14 | $203 |
| Boehringer Ingelheim | 13 | $181 |
| Amgen | 10 | $160 |
| Astellas Pharma US Inc | 4 | $153 |
| AbbVie(2 entities) | 9 | $132 |
| Novartis | 6 | $91 |
| Esperion Therapeutics, Inc. | 5 | $82 |
| Johnson & Johnson | 4 | $72 |
| Abbott | 4 | $67 |
| Pfizer | 5 | $66 |
| Lilly USA, LLC | 4 | $54 |
| Biogen | 4 | $54 |
| Genentech USA, Inc. | 3 | $39 |
| Bausch Health US, LLC | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Medtronic | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
How this compares
$2,370 in reported general payments places this provider in the 90th percentile of 2,591 general practice providers in Virginia.
Other general practice in Suffolk
- Maryam SabaSpringfield$811K
- Perry JonesRichmond$489K
- Nancy ReevesNorfolk$411K
- Adam HamidiSalem$177K
- Shane CostaReston$174K
- Donald MurryPowhatan$157K
- Marcus YarbroughVirginia Beach$154K
- Adam FoleckNorfolk$149K
- David JonesVirginia Beach$126K
- David BabingtonChantilly$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.